In this article DXCM Follow your favorite stocks CREATE FREE ACCOUNT Kevin Sayer, CEO, Dexcom Scott Mlyn | CNBC Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts' expectations but showed a decline in U.S. revenue year over year.
Here's how the company did: Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEG Revenue: $994 million vs. $990 million expected by LSEG The company's revenue increased 2% to $994.
2 million from $975 million a year earlier. Dexcom's U.S.
revenue declined 2% from $713.6 million the prior year. The company reported net income of $134.
6 million, or 34 cents per share, up from $120.7 million, or 29 cents per share, in the same period last year. Dexcom offers a suite of tools like continuous glucose monitors (CGMs) for patients who have been diagnosed with diabetes.
In August, it launched its first over-the-counter product called Stelo, which is intended for adults who do not take insulin. The company maintained its full fiscal year guidance and expects revenue of $4 billion to $4.05 billion.
Last quarter, Dexcom lowered its guidance from the $4.20 billion to $4.35 billion it forecast in the first quarter .
This lowered guidance and a revenue miss caused Dexcom shares to tumble more than 40% following the release of its second-quarter results in July. The company's CEO Kevin Sayer attributed the challenges to a restructuring of the company's sales team, fewer new cust.